-Universitätsklinikder

[21] Cherny, N. I., Thaler, H. T., Friedlander-Klar, H., Lapin, J., Foley, K. M.,
Houde, R., Portenoy, R. K. (1994). Opioid responsiveness of cancer pain
syndromes caused by neuropathic or nociceptive mechanisms: a combined
analysis of controlled, single-dose studies. Neurology 44 (5), 857–861
[22] Chow, E., Doyle, M., Li, K., Bradley, N., Harris, K., Hruby, G., Sinclair, E.,
Barnes, E. A., Danjoux, C. (2006). Mild, moderate, or severe pain
categorized by patients with cancer with bone metastases. J Palliat Med 9
(4), 850–854
[23] Chua, K. S. ., Reddy, S. K., Lee, M.-C., Patt, R. B. (1999). Pain and Loss of
Function in Head and Neck Cancer Survivors. Journal of Pain and
Symptom Management 18 (3), 193–202
[24] Clark, D. (1999). „Total pain“, disciplinary power and the body in the work of
Cicely Saunders, 1958-1967. Soc Sci Med 49 (6), 727–736
[25] Cleeland, C. S., Farrar, J. T., Hausheer, F. H. (2010). Assessment of
cancer-related neuropathy and neuropathic pain. Oncologist 15 (2), 13–18
[26] Cleeland, C. S., Gonin, R., Hatfield, A. K., Edmonson, J. H., Blum, R. H.,
Stewart, J. A., Pandya, K. J. (1994). Pain and Its Treatment in Outpatients
with Metastatic Cancer. New England Journal of Medicine 330 (9), 592–596
[27] Cohen, K. L., Harris, S. (1987). Efficacy and safety of nonsteroidal antiinflammatory
drugs in the therapy of diabetic neuropathy. Arch. Intern. Med.
147 (8), 1442–1444
[28] de Oliveira, R., Reis, M. P. dos, Prado, W. A. (2004). The effects of early or
late neurolytic sympathetic plexus block on the management of abdominal
or pelvic cancer pain. Pain 110 (1-2), 400–408
[29] Deutsche Gesellschaft für, W.-Kohlhammer-GmbH. (2015). S3-Leitlinie
Palliativmedizin für Patienten mit einer nicht heilbaren Krebserkrankung.
Kohlhammer, Stuttgart 9, 85–86
[30] Dickenson, A. (2010). CHANGE PAIN- The neuropharmacology of pain and
its control. Gehalten auf der International CHANGE PAIN Expert Summit,
Rome, Italy, 1–36
64